Premium
Cannabidiol, extracted from Cannabis sativa , selectively inhibits inflammatory hypermotility in mice
Author(s) -
Capasso R,
Borrelli F,
Aviello G,
Romano B,
Scalisi C,
Capasso F,
Izzo A A
Publication year - 2008
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1038/bjp.2008.177
Subject(s) - cannabidiol , cannabinoid , pharmacology , cannabinoid receptor , (+) naloxone , cannabinoid receptor antagonist , chemistry , fatty acid amide hydrolase , cannabinoid receptor type 2 , endocannabinoid system , antagonist , biology , receptor , biochemistry , medicine , cannabis , psychiatry
Background and purpose: Cannabidiol is a Cannabis‐ derived non‐psychotropic compound that exerts a plethora of pharmacological actions, including anti‐inflammatory, neuroprotective and antitumour effects, with potential therapeutic interest. However, the actions of cannabidiol in the digestive tract are largely unexplored. In the present study, we investigated the effect of cannabidiol on intestinal motility in normal (control) mice and in mice with intestinal inflammation. Experimental approach: Motility in vivo was measured by evaluating the distribution of an orally administered fluorescent marker along the small intestine; intestinal inflammation was induced by the irritant croton oil; contractility in vitro was evaluated by stimulating the isolated ileum, in an organ bath, with ACh. Key results: In vivo , cannabidiol did not affect motility in control mice, but normalized croton oil‐induced hypermotility. The inhibitory effect of cannabidiol was counteracted by the cannabinoid CB 1 receptor antagonist rimonabant, but not by the cannabinoid CB 2 receptor antagonist SR144528 ( N ‐[‐1 S ‐ endo ‐1,3,3‐trimethyl bicyclo [2.2.1] heptan‐2‐yl]‐5‐(4‐chloro‐3‐methylphenyl)‐1‐(4‐methylbenzyl)‐pyrazole‐3‐carboxamide), by the opioid receptor antagonist naloxone or by the α 2 ‐adrenergic antagonist yohimbine. Cannabidiol did not reduce motility in animals treated with the fatty acid amide hydrolase (FAAH) inhibitor N ‐arachidonoyl‐5‐hydroxytryptamine, whereas loperamide was still effective. In vitro , cannabidiol inhibited ACh‐induced contractions in the isolated ileum from both control and croton oil‐treated mice. Conclusions and implications: Cannabidiol selectively reduces croton oil‐induced hypermotility in mice in vivo and this effect involves cannabinoid CB 1 receptors and FAAH. In view of its low toxicity in humans, cannabidiol may represent a good candidate to normalize motility in patients with inflammatory bowel disease. British Journal of Pharmacology (2008) 154 , 1001–1008; doi: 10.1038/bjp.2008.177 ; published online 12 May 2008